HRD-Portal

QuIP is committed to supporting pathologists in Germany and Europe in all aspects of professional and organizational quality assurance. 

The HRD-Portal provides pathologists and other medical professionals with guidance and information at the intersection of biomarker testing and therapy. This website serves as an interdisciplinary resource, supporting diagnostics, molecular pathology, and therapy planning.

The portal provides an overview of DNA repair defects, explaining the testing of underlying causes, such as mutations in HRR genes (including BRCA1/2), and the resulting effects (e.g. GI score). The algorithm offers detailed information on tests, possible outcomes, and therapy options for various cancer entities (pancreatic, ovarian, breast, and prostate cancer). The content is based on current medical guidelines (EMA-approved) and the latest scientific research.

References on the Portal

The underlying scientific literature used to create the portal content is listed in a separate 'References' tab, cited for the corresponding sections of the algorithm. This research literature reflects the current work status of the portal's editorial team and is continuously updated or supplemented as needed.

Disclaimer

Please note: The information provided on our HRD Portal is shared to the best of our knowledge. However, we cannot guarantee the completeness, accuracy, or timeliness of the content. This is especially true for content that originates from third parties and is merely linked on our website. For the most current and detailed information on the medications, the respective technical information should be consulted.

Qualitätssicherungs-Initiative Pathologie GmbH

QuIP is supported by AstraZeneca, GlaxoSmithKline, Janssen-Cilag, MSD Sharp & Dohme and Pfizer.